📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo. (2018)

First Author: Thompson KJ

Attributed to: MICA Pharmacological, molecular and cellular mechanisms of muscarinic slowing (modification) of neurodegenerative disease. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1021/acsptsci.8b00012

PubMed Identifier: 30868140

Publication URI: http://europepmc.org/abstract/MED/30868140

Type: Journal Article/Review

Volume: 1

Parent Publication: ACS pharmacology & translational science

Issue: 1

ISSN: 2575-9108